Qiagen Sells Synthetic DNA Business, Inks siRNA Supply Deal with AstraZeneca
Qiagen announced this week that it has sold its synthetic DNA business to a management team previously employed by the company and which operated parts of this business. Qiagen said that it will retain all rights to its siRNA business.
Under the terms of the deal, Qiagen will receive $24.3 million, $17.8 million of which is in cash with the remainder in a promissory note. Qiagen will also retain a 16 percent stake in the business, which will be named Operon Biotechnologies.